Sutro Biopharma, Inc. (STRO) Value Adjusted for Debt and Cash

Sutro Biopharma, Inc (STRO) - corporate logo

Sutro Biopharma, Inc. (STRO) is implementing unique cell-free synthesis for the rapid design of precise anti-tumor molecules. The share price history shows a current value of 232.57. Business growth is driven by the demand for targeted therapy and partnerships with global corporations. Sustainable development is guaranteed by a team of leading protein engineers dedicated to the company's innovative scientific research.

STRO (Sutro Biopharma, Inc.) Total Company Value history from 11/23/2025 to 10/28/2026

Sutro Biopharma, Inc. - analytical breakdowns and key metrics (STRO)

- price and consensus price forecast:
Price Sutro Biopharma Inc.|STRO - Price Target Chart
- market capitalization data:
Market Value Sutro Biopharma|STRO - Total Company Value
- book capitalization data:
Net Asset Value per Share Sutro Biopharma|STRO - Company Book Value|Market-to-Book Ratio sutrobio.com|STRO - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Sutro Biopharma, Inc.|STRO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio sutrobio.com|STRO - Company Debts|Debts to Book Value Sutro Biopharma
Fundamental valuation:Sutro Biopharma Inc. (STRO)
Original product of Sutro Biopharma

Sutro Biopharma, Inc. (STRO) is developing a unique protein synthesis platform to create affordable anti-cancer drugs. Enterprise Value (EV) combines market capitalization with debt, subtracting available cash. This algorithm determines the actual volume of investment required for a full buyout of the business. The metric allows for an assessment of how much the market currently prices in the potential for production scalability. The Enterprise Value (EV) trend reflects the balance between asset value and financial risks.

Competitors of Sutro Biopharma, Inc. (STRO)

ImmunityBio Inc - Aggregate Business Value|Total Company Value Immunocore PLC (IMCR)|JANX: Value Adjusted for Debt and Cash|Total Company Value RCUS|ZYME (zymeworks.com) - Total Enterprise Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|replimune.com - Real Price to Acquire Entire Company|LYEL (Lyell Immunopharma, Inc.) - Total Company Value|IPHA: Total Enterprise Value|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IOBT (IO Biotech, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)